2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1856

Burden of Adverse Events Associated with Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review
Abstract Number: 304

Burden of Childhood Central Nervous System Vasculitis: Identifying High Risk Factors for Poor Cognitive Outcome
Abstract Number: 1017

Bye Bye Biopsy: Diffusion Tensor and Dynamic Contrast Enhance Magnetic Resonance Imaging Parameters Reflect Molecular Events of Inflammation in the Synovium
Abstract Number: 852

C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis
Abstract Number: 1321

C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis
Abstract Number: 2682

Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Systemic Lupus Erythematosus
Abstract Number: 1273

Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment?
Abstract Number: 399

Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Abstract Number: 401

Can We Improve Outcomes in Early Rheumatoid Arthritis by Determining Best Practices? An Analysis of the Canadian Early Rheumatoid Arthritis Cohort (CATCH)
Abstract Number: 99

Cancer Iincidence and Type of Malignancy in Rrheumatologic Ddiseases in Korea: Head-to-Head Comparison
Abstract Number: 2475

Cancer in Pediatric-Onset Systemic Lupus: What Is the Role of Disease Duration and Other Factors on Risk?
Abstract Number: 1039

Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging
Abstract Number: 1198

Cardiovascular Risk Factors and Events Are More Frequent Prior to the Onset of Rheumatoid Arthritis Than in the General Population
Abstract Number: 68

Cardiovascular Comorbidities Antedating the Diagnosis of Rheumatoid Arthritis
Abstract Number: 2404

Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].